Cancer
August 1, 2026 · via Europe PMC
Blinatumomab administration in the outpatient setting: Safety and health care utilization.
Valtis YK, Frost BF, Nemirovsky D, +14 more, Chen EC.
AI summary — for doctors, generated from the abstract only
Outpatient initiation of blinatumomab cycle 2 for B-ALL was safe, with no grade 3+ CRS among 184 patients who started cycle 2.
What was studied
Retrospective two-center cohort (MSK and DFCI, 2012-2025) of 308 patients receiving blinatumomab, comparing inpatient vs outpatient initiation of cycles.
Key findings
- Only 3% started cycle 1 outpatient
- Cycle 2 outpatient start: 12% at DFCI vs 88% at MSK
- No grade 3+ CRS in any cycle-2 starters; 2 grade 3+ ICANS, both inpatient
- 19% of outpatient cycle-2 patients needed hospitalization, mostly for infections
Clinical relevance
This suggests preemptive hospitalization for blinatumomab cycle 2 may be unnecessary in selected patients, potentially improving patient experience and cost.
Who should care
Limitations
Retrospective design with institution-dependent practice patterns; cycle 1 outpatient data very limited.
Blinatumomab cycle 2 can safely start outside the hospital for many patients.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Background
Blinatumomab, a bispecific CD19 × CD3 antibody is effective for the treatment of B-cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (FDA) recommends preemptive hospitalization for the initiation of cycle 1 (C1) and cycle 2 (C2). The necessity of this approach is unclear.
Methods
The authors conducted a retrospective cohort study among all patients treated with blinatumomab between 2012 and 2025 at two academic cancer centers: Memorial Sloan Kettering Cancer Center (MSK) and Dana-Farber Cancer Institute (DFCI).
Results
For C1, only nine of 308 (3%) patients initiated outpatient (OP) treatment. A total of 184 of 308 (60%) initiated C2: At DFCI, 10 of 83 (12%) initiated C2 OP and at MSK, and 74 of 101 (88%) initiated C2 OP. Demographic and clinical characteristics were similar between patients initiating C2 inpatient versus OP. No patients who initiated C2 (0 of 184) had Gr3+ CRS (across all cycles) and only two (1%) had Gr3+ ICANS; both were inpatient for C2. Of 84 patients treated without preemptive hospitalization for C2, 16 of 84 (19%) required hospitalization at some point during the cycle, largely for infections (50%).
Conclusions
OP administration of C2 of blinatumomab can be administered safely with no unexpected, severe, or life-threatening toxicities. The ability to safely manage treatment without preemptive hospitalization may support the patient experience and limit costs of care.
DOI
10.1002/cncr.70566
PMID
42610826
PMCID
PMC13484548
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed